Title

Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
A Single Treatment, Pharmacokinetic (PK) and Tolerance Study of Natroba (Spinosad) Topical Suspension, 0.9% in Pediatric Subjects 6 Months to 4 Years of Age With an Active Head Lice Infestation
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Intervention/Treatment

    spinosad ...
  • Study Participants

    26
A pharmacokinetic and tolerance study of Natroba (spinosad) Topical Suspension, 0.9% in pediatric subjects 6 months to 4 years of age with an active head lice infestation.
A Postmarketing Requirement Protocol, multicenter, open-label study in pediatric subjects 6 months to 4 years of age with an active head lice infestation designed to determine the topical absorption and safety of Natroba (spinosad) Topical Suspension, 0.9% for a single, 10 minute treatment for spinosad (Spinosyn A and Spinosyn D) and benzyl alcohol.
Study Started
Sep 30
2011
Primary Completion
Oct 31
2011
Study Completion
Mar 31
2012
Results Posted
Nov 19
2012
Estimate
Last Update
Nov 22
2012
Estimate

Drug spinosad

A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.

  • Other names: Natroba (spinosad) Topical Suspension, 0.9%

Natroba Experimental

Natroba (Spinosad) Topical Suspension, 0.9%

Criteria

Inclusion Criteria:

Male or female, 6 months to 4 years of age.
Subjects must have had an active lice infestation including live lice.
Individuals in otherwise good general health, free of any systemic or dermatologic disorders which, in the opinion of the Principal Investigator or designee, would interfere with the study results or increase the risk of adverse events.
A parent (or guardian) must have signed an Informed Consent Form to allow any child to participate in the study.
Subjects must have been available to stay in the clinic for blood draws. Parents or guardians must have been available to stay in the clinic, with the subject, for the entire duration of the study.
Subjects must have had veins capable of insertion of a Heplock catheter or withstanding multiple blood draws as determined by the Principal Investigator or qualified phlebotomist.
Normal values (at screening) for serum chemistry and hematology for subjects, unless the principal Investigator or qualified medical designee determined that the abnormal value was not clinically significant.

Exclusion Criteria:

History of irritation or sensitivity to pediculicide or hair care products or ingredients.
History of known allergy or sensitivity to topical anesthetics including lidocaine and prilocaine.
History of allergy or sensitivity to Heparin.
Systemic diseases that could have interfered with the results of this study as determined by the Principal Investigator or designee.
Any condition or illness that, in the opinion of the Investigator or designee, may have compromised the objective of the protocol or the safety of the subject.
The use of antibiotics or other systemic medications within 2 weeks of the screening visit, which in the opinion of the Investigator or designee could have interfered with the outcome of the study.
Participation in a previous drug study within the past 30 days.
Individuals with any visible skin/scalp condition (other than from an active lice infestation) at the treatment site which would have interfered with the evaluations according to the opinion of the Investigator or designee.
Parents or guardians who, in the opinion of the Investigator, did not understand their child's requirements for study participation and/or may be likely to exhibit poor compliance.

Summary

Natroba

All Events

Event Type Organ System Event Term Natroba

Cmax for Spinosyn A

Peak Plasma Concentration of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%

Natroba

Tmax for Spinosyn A

The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn A.

Natroba

AUC (0-12) for Spinosyn A

Area under the plasma concentration versus time curve (AUC) of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%.

Natroba

Cmax for Spinosyn D

Peak Plasma Concentration of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%

Natroba

Tmax for Spinosyn D

The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn D.

Natroba

AUC (0-12) for Spinosyn D

Area under the plasma concentration versus time curve (AUC) of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%.

Natroba

Cmax for Benzyl Alcohol

Peak Plasma Concentration of benzyl alcohol (above Limit of Quantitation (1.0 μg/mL) in Natroba (spinosad) Topical Suspension, 0.9%.

Natroba

1.123
μg/mL (Mean)
Standard Deviation: 0.3071

Tmax for Benzyl Alcohol

The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for benzyl alcohol.

Natroba

0.5
hours (Median)
Full Range: 0.3071

AUC (0-12) for Benzyl Alcohol

Area under the plasma concentration versus time curve (AUC) of benzyl alcohol in Natroba (spinosad) Topical Suspension, 0.9%.

Natroba

Age Continuous

2
years (Mean)
Standard Deviation: 0.9

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Natroba